866-997-4948(US-Canada Toll Free)

Constipation - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 119 Pages

Constipation - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2017, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 10, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Constipation - Overview
Constipation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Constipation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Constipation - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Allergan Plc
Ardelyx Inc
Astellas Pharma Inc
Braintree Laboratories Inc
Dong-A ST Co., Ltd.
EA Pharma Co Ltd
Ironwood Pharmaceuticals Inc
Johnson & Johnson
Kissei Pharmaceutical Co Ltd
NGM Biopharmaceuticals Inc
RaQualia Pharma Inc
Sanwa Kagaku Kenkyusho Co Ltd
SK Biopharmaceuticals Co Ltd
Sucampo Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Synergy Pharmaceuticals Inc
Synthetic Biologics Inc
Torrent Pharmaceuticals Ltd
Vanda Pharmaceuticals Inc
Yuhan Corp
Zensun (Shanghai) Sci & Tech Co Ltd
Constipation - Drug Profiles
5-BIOP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AJG-555 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7663 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-6952 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elobixibat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
J-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KWA-0711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide DR1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lovastatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plecanatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relenopride hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-12852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZS-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Constipation - Dormant Projects
Constipation - Product Development Milestones
Featured News & Press Releases
Jun 27, 2017: Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation
Jun 07, 2017: Synergy Pharmaceuticals Announces Acceptance of Supplemental New Drug Application (sNDA) for TRULANCE (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation
May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
May 09, 2017: Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide's Effect on Pain at Digestive Disease Week 2017
May 07, 2017: Synergy Pharmaceuticals to Present TRULANCE (Plecanatide) Phase 3 Data at Digestive Disease Week for the Treatment of Adults with Chronic Idiopathic Constipation with Moderate to Very Severe Bloating
May 07, 2017: Synergy Presents New Insights at Digestive Disease Week (DDW) Examining Patient and Physician Perceptions and Experiences with Chronic Idiopathic Constipation
May 01, 2017: Allergan to Present Linzess and Linaclotide Delayed Release Data at Digestive Disease Week 2017
May 01, 2017: Synergy Pharmaceuticals to Highlight New Data for TRULANCE (Plecanatide) at Digestive Disease Week
Apr 12, 2017: Synergy Pharmaceuticals Announces Issuance of Three New Patents Expected to Extend TRULANCE (Plecanatide) Patent Protection Until 2032
Mar 27, 2017: Synergy Pharmaceuticals Submits Supplemental New Drug Application for TRULANCE (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation
Mar 22, 2017: Astellas Pharma Announces Launch of LINZESS Tablets 0.25mg in Japan
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program Linaclotide delayed release-1 at R&D Day 2017
Feb 07, 2017: Pivotal Phase 3 Data Results for TRULANCE (plecanatide) in the Treatment of Chronic Idiopathic Constipation (CIC) Published in American Journal of Gastroenterology
Feb 01, 2017: Albireo Announces Submission of New Drug Application for Elobixibat in Japan
Jan 30, 2017: Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Constipation, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Constipation - Pipeline by Albireo Pharma Inc, H2 2017
Constipation - Pipeline by Allergan Plc, H2 2017
Constipation - Pipeline by Ardelyx Inc, H2 2017
Constipation - Pipeline by Astellas Pharma Inc, H2 2017
Constipation - Pipeline by Braintree Laboratories Inc, H2 2017
Constipation - Pipeline by Dong-A ST Co., Ltd., H2 2017
Constipation - Pipeline by EA Pharma Co Ltd, H2 2017
Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
Constipation - Pipeline by Johnson & Johnson, H2 2017
Constipation - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Constipation - Pipeline by NGM Biopharmaceuticals Inc, H2 2017
Constipation - Pipeline by RaQualia Pharma Inc, H2 2017
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2017
Constipation - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
Constipation - Pipeline by Sucampo Pharmaceuticals Inc, H2 2017
Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Constipation - Pipeline by Synergy Pharmaceuticals Inc, H2 2017
Constipation - Pipeline by Synthetic Biologics Inc, H2 2017
Constipation - Pipeline by Torrent Pharmaceuticals Ltd, H2 2017
Constipation - Pipeline by Vanda Pharmaceuticals Inc, H2 2017
Constipation - Pipeline by Yuhan Corp, H2 2017
Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2017
Constipation - Dormant Projects, H2 2017

List of Figures
Number of Products under Development for Constipation, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *